Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Yesterday, Nov. 20, 2014, 118 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $277.00 to $8,954,563.40.

Highlighted Stocks Traded by Insiders:

Insys Therapeutics (INSY) - FREE Research Report

Fourteau Patrick, who is Director at Insys Therapeutics, sold 25,000 shares at $39.11 on Nov. 20, 2014. Following this transaction, the Director owned 80,000 shares meaning that the stake was reduced by 23.81% with the 25,000-share transaction.

The shares most recently traded at $39.25, up $0.14, or 0.36% since the insider transaction. Historical insider transactions for Insys Therapeutics go as follows:

  • 4-Week # shares bought: 16,500
  • 4-Week # shares sold: 1,262
  • 12-Week # shares bought: 16,500
  • 12-Week # shares sold: 1,262
  • 24-Week # shares bought: 16,500
  • 24-Week # shares sold: 1,262

The average volume for Insys Therapeutics has been 481,500 shares per day over the past 30 days. Insys Therapeutics has a market cap of $1.3 billion and is part of the health care sector and drugs industry. Shares are up 51.01% year-to-date as of the close of trading on Thursday.

Insys Therapeutics, Inc., a commercial-stage specialty pharmaceutical company, develops and commercializes supportive care products. It focuses on utilizing its proprietary formulation technologies to address the clinical shortcomings of existing commercial pharmaceutical products. The company has a P/E ratio of 24.6. Currently, there are 3 analysts who rate Insys Therapeutics a buy, no analysts rate it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on INSY - FREE

TheStreet Quant Ratings rates Insys Therapeutics as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Insys Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

LinkedIn (LNKD) - FREE Research Report

Taylor Susan J.S., who is VP, Corporate Controller & CAO at LinkedIn, sold 1,345 shares at $218.75 on Nov. 20, 2014. Following this transaction, the VP, Corporate Controller & CAO owned 12,065 shares meaning that the stake was reduced by 10.03% with the 1,345-share transaction.

The shares most recently traded at $223.72, up $4.97, or 2.22% since the insider transaction. Historical insider transactions for LinkedIn go as follows:

  • 4-Week # shares sold: 17,297
  • 12-Week # shares sold: 23,297
  • 24-Week # shares sold: 75,729

The average volume for LinkedIn has been 1.8 million shares per day over the past 30 days. LinkedIn has a market cap of $23.8 billion and is part of the technology sector and internet industry. Shares are up 1.6% year-to-date as of the close of trading on Thursday.

LinkedIn Corporation operates an online professional network. Currently, there are 19 analysts who rate LinkedIn a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LNKD - FREE

TheStreet Quant Ratings rates LinkedIn as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income and disappointing return on equity. Get the full LinkedIn Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Imperva (IMPV) - FREE Research Report

Kraynak Mark E., who is Chief Product Officer at Imperva, sold 6,140 shares at $42.00 on Nov. 20, 2014. Following this transaction, the Chief Product Officer owned 10,000 shares meaning that the stake was reduced by 38.04% with the 6,140-share transaction.

The shares most recently traded at $42.80, up $0.80, or 1.87% since the insider transaction. Historical insider transactions for Imperva go as follows:

  • 4-Week # shares sold: 11,513
  • 12-Week # shares sold: 12,513
  • 24-Week # shares sold: 17,599

The average volume for Imperva has been 447,300 shares per day over the past 30 days. Imperva has a market cap of $1.1 billion and is part of the technology sector and computer software & services industry. Shares are down 12.4% year-to-date as of the close of trading on Thursday.

Imperva, Inc. develops, markets, sells, services, and supports data center security solutions that protect high value applications and data assets in physical and virtual data centers. The company operates in two segments, Imperva and Incapsula. Currently, there are 7 analysts who rate Imperva a buy, no analysts rate it a sell, and 2 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on IMPV - FREE

TheStreet Quant Ratings rates Imperva as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Imperva Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null